Claims

1. A process for vitreous liquefaction comprising the steps of:

delivering a dose of a plasmin composition into a vitreous body of a subject eye; and

incubating the plasmin composition in the vitreous body for a predetermined amount of time.

2. The process of claim 1 wherein the delivering is by injection.

3. The process of claim 1 wherein the delivering is by infusion.

4. The process of claim 1 wherein the delivering is by sustained release intraocular device.

5. The process of claim 1 wherein the plasmin composition comprises human plasmin.

6. The process of claim 1 wherein the plasmin composition comprises autologous human plasmin.

7. The process of claim 1 wherein the plasmin composition comprises an accompaniment selected from the group consisting of: an enzyme, a glycoprotein, a polysaccharide, an antibiotic, a pharmaceutically

acceptable diluent, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable carrier.

8. The process of claim 1 further comprising the step of delivering a plasmin inhibitor.

9. The process of claim 1 wherein the subject eye has a pathological condition.

10. The process of claim 9 wherein the pathological condition is selected from the group consisting of: diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

11. The process of claim 1 wherein the dose of a plasmin composition comprises between 0.01 and 5.0 units of plasmin.

12. The process of claim 1 wherein the dose of a plasmin composition comprises between 0.1 and 1.0 units of plasmin.

13. The process of claim 1 wherein the predetermined amount of time is ten minutes and two hours.

14. A process for vitreous liquefaction comprising the steps of:

delivering a dose of a plasmin composition comprising autologous plasmin into a vitreous body of a subject eye; and

incubating the plasmin composition in the vitreous body for a predetermined amount of time.

15. The process of claim 14 wherein the delivering is by injection.

16. The process of claim 14 wherein the delivering is by infusion.

17. The process of claim 14 wherein the delivering is by sustained release intraocular device.

18. The process of claim 14 wherein the plasmin composition comprises an accompaniment selected from the group consisting of: an enzyme, a glycoprotein, a polysaccharide, an antibiotic, a pharmaceutically acceptable diluent, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable carrier.

19. The process of claim 14 further comprising the step of delivering a plasmin inhibitor.

20. The process of claim 14 wherein the subject eye has a pathological condition.

21. The process of claim 20 wherein the pathological condition is selected from the group consisting of: diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

22. The process of claim 14 wherein the dose of a plasmin composition comprises between 0.01 and 5.0 units of plasmin.

23. The process of claim 14 wherein the dose of a plasmin composition comprises between 0.1 and 2.0 units of plasmin.

24. The process of claim 14 wherein the predetermined amount of time is ten minutes and two hours.